CPHI’s Post

Financial Times's U.S. Pharma and Biotech Summit will take place in New York on May 16. Panel sessions will dive into funding pharma and biotech innovation, AI, pharma workforces and more. More details in this article from Pharmaceutical Executive: #pharma | #biotech | #innovation | #healthcare

How does #xMAP Technology propel pharmaceutical innovation? Join us at the Drug Discovery & Development Virtual Event Series 2024 hosted by Labroots to find out. 🌟 Presentation: “Multiplexed mapping of the GPCR-RAMP interactome” 🎙️Speaker: Dr. Jochen Schwenk, Professor at KTH Royal Institute of Technology 📅 Date: Wednesday, February 21st 🕛 Time: 11:30 am PST GPCRs are vital membrane proteins involved in cellular and physiological processes, and understanding their function and regulation is essential for developing targeted therapies for human diseases. Learn how Dr. Jochen Schwenk and his team at KTH Royal Institute of Technology utilize xMAP Technology in a multi-modal analysis of the membrane bound receptors, revealing interactions with system-wide implications for GPCR regulation. Stop by the Luminex booth after the presentation, or anytime throughout the day, to learn more about xMAP Technology and gain access to all our latest white papers, videos, and other helpful resources. Save your spot now: https://hubs.li/Q02ln_-l0 #DrugDiscovery #DrugDevelopment #PreclinicalDevelopment #Multiplexing #xMAPTechnology #GPCRs #Pharmacogenomics #BiomarkerApplications #Labroots #HealthcareInnovation #Biopharma #MultiModal

🌟 Big News from Elixirgen Scientific Japan! 🌟 🏆 We've been named as one of the TOP 10 CDMOs in APAC - 2023 by Pharma Tech Outlook! This prestigious award recognizes our unwavering dedication to excellence in synthetic mRNA contract development and manufacturing. Since launching our CDMO services in September 2021, we've made remarkable strides in mRNA manufacturing, contributing greatly to advancements in this vital field. Our journey has been one of relentless innovation and commitment to quality, and this recognition is a testament to the hard work and expertise of our incredible team. 🙌 🔗: https://lnkd.in/dnmkXgW2 Let's keep pushing the boundaries of what's possible in regenerative medicine and drug development. Here's to more breakthroughs and continued success in the years to come! 💡🧬 #ElixirgenScientific #ElixirgenScientificJapan #mRNA #Biotechnology #Pharmaceuticals #Innovation #CDMO

Alexander Zehnder, MD, MBA gives an update on the #mRNA field during the 11th annual mRNA Health Summit in Berlin, short video here:https://lnkd.in/e2JG3CPA multiple presentations by Nobel prize winner Katalin Karikó were an obvious highlight, as were the innovative scientific presentations, poster session, exhibits - but especially the shared sense of camaraderie and energy for this burgeoning field. The launch of the Alliance for mRNA Medicines also reinvigorated 2024 project plans and partnership strategies, alongside hope for a more unified regulatory landscape amongst all geographies - both physical and political. #pharmaceutical #mrnavaccines #pandemic #oncologyresearch #crispr #cartcelltherapy thanks to Moderna and BioNTech SE, but especially CureVac as Berlin hosts. Thanks also to BioPharm International

Reuters Pharma USA 2024 Day 1 - The event showcased groundbreaking advancements in the pharmaceutical industry. - Key topics included the integration of artificial intelligence in drug discovery, personalized medicine, and the impact of regulatory changes on drug approval processes. - Speakers highlighted the potential of AI to streamline drug development, improve patient outcomes, and reduce costs. - Discussions also revolved around the growing importance of data analytics in optimizing clinical trials and predicting drug efficacy. - Attendees explored innovative strategies for tackling emerging health challenges, such as infectious diseases and mental health disorders. - Moreover, the event emphasized the importance of collaboration between pharmaceutical companies, regulatory bodies, and healthcare providers to drive innovation and ensure patient access to cutting-edge treatments. Overall, the event provided a comprehensive overview of the latest trends and developments shaping the future of the pharmaceutical landscape in the United States. #ReutersPharmaUSA2024 #REpharmaUSA AKT Health Inc.

We're thrilled to announce the official launch of the Biospecimen Management Consortium, an alliance of industry leaders committed to driving sample excellence in clinical research. Founding members — including GRAIL, GSK, ILiAD Biotechnologies, LLC, Moderna, Novartis, Roche, Takeda, and Teal Health — will address longstanding inefficiencies and gaps in biospecimen lifecycle management that must be addressed to improve data quality and patient outcomes. Together, the consortium will: - Develop best practices and industry standards - Streamline biospecimen lifecycle operations and data management - Shape the future of regulatory policy We look forward to working with these organizations to transform biosample operations, and we commend them for their unwavering dedication to creating a brighter future in clinical research. To read the full press release, click here: https://lnkd.in/gKxTBBRp #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials

🌟 Exciting News from Biophytis! 🌟 We're thrilled to announce our participation in the BIO-Europe conference in Munich from Nov 6-8, 2023. This event is a cornerstone for industry leaders in pharma and biotech to connect and collaborate. Our Chief Business Officer, Edouard B., is set to engage with key decision-makers to explore co-development and commercialization partnerships for Sarconeos (BIO101), our leading drug candidate aimed at combating severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy. Joining BIO-Europe aligns with our strategic goal to expedite Sarconeos (BIO101) to markets across the US, Europe, Asia, and South America. We're committed to advancing treatment options and improving patient outcomes in age-related diseases. For more details, read our full press release here: https://lnkd.in/ekWTqMUi Stay tuned for more updates! #Biophytis #BIOEurope2023 #Sarconeos #BIO101 #Biotech #Pharmaceuticals #Aging #HealthcareInnovation

Exciting Announcement from BioPharm International! We are thrilled to launch our new Peer Exchange video series, offering a unique platform for vibrant discussions and peer-to-peer knowledge transfer. This series aims to provide authoritative insights, opinions, and sharing of best practices on the critical issues facing today's pharmaceutical manufacturing professionals. Don't forget to follow our page for the latest updates! In our first video interview, Chris Spivey, Director of Industry Relations and Strategic Partnerships at BioPharm International, engages with industry experts: Dr. Peter Marks from the FDA, Dr. Foud Atouf from US Pharmacopeia, Kenneth Chien, PhD from Moderna and the Karolinska Institutet, and Constanze Blume from BioNTECH on the scientific and commercial progress of mRNA technology and its intersection with compliance and regulatory streamlining. Key discussion points include: - Gaining leverage from capacity built during the pandemic, and ways to leverage against future pandemics - Increasing knowledge of self-amplifying RNA (saRNA) or circular RNA (circRNA) handling and manufacturing aspects - Defining which mRNA Critical Quality Attributes (CQA) and Critical process parameters (CPP) in pharmaceutical manufacturing are key variables to influence the production process - Learning how to incorporate these attributes and parameters when considering mRNA production as a potential regulatory platform pathway Stay tuned as we delve into these important topics! #mRNA #PersonalizedMedicine #PeerExchange #Innovation #Healthcare #Pharmaceuticals #IndustryInsights

New Peer Exchange from BioPharm International is now live! In our first video interview, Chris Spivey, Director of Industry Relations and Strategic Partnerships at BioPharm International, engages with industry experts: Dr. Peter Marks from the FDA, Dr. Foud Atouf from US Pharmacopeia, Kenneth Chien, PhD from Moderna and the Karolinska Institutet, and Constanze Blume from BioNTECH on the scientific and commercial progress of mRNA technology and its intersection with compliance and regulatory streamlining. Key discussion points include: - Gaining leverage from capacity built during the pandemic, and ways to leverage against future pandemics - Increasing knowledge of self-amplifying RNA (saRNA) or circular RNA (circRNA) handling and manufacturing aspects - Defining which mRNA Critical Quality Attributes (CQA) and Critical process parameters (CPP) in pharmaceutical manufacturing are key variables to influence the production process - Learning how to incorporate these attributes and parameters when considering mRNA production as a potential regulatory platform pathway Watch Now: https://ow.ly/f8xG50Sz3OL #mRNA #PersonalizedMedicine #PeerExchange #Innovation #Healthcare #Pharmaceuticals #IndustryInsights

🎉 Exciting news! Eight leading organizations in the clinical trials industry have united as founding members of the Biospecimen Management Consortium, hosted by Slope. The BMC will spearhead initiatives to set best practices, establish industry standards, streamline biospecimen lifecycle operations, enhance data management, and shape regulatory policy. Stay tuned for updates on their journey @BiospecimenManagementConsortium and dive into their goals at the link below. #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials